LCQ908
Sponsors
Novartis Pharmaceuticals
Conditions
Familial Chylomicronemia Syndrome (FCS)Familial Chylomicronemia Syndrome (FCS) (HLP Type I)Hepatic ImpairmentHepatitis CHyperlipoproteinemiaNon Familial Chylocmicronemia Syndrome (Non-FCS)Non-alcoholic Fatty Liver Disease (NAFLD)Renal Impairment
Phase 1
Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia
CompletedNCT01146522
Start: 2010-05-31End: 2011-10-31Updated: 2020-12-17
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
CompletedNCT01558323
Start: 2012-05-31End: 2013-03-31Updated: 2020-12-19
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
CompletedNCT01594957
Start: 2012-04-30End: 2013-04-30Updated: 2020-12-19
Phase 2
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
TerminatedNCT01387958
Start: 2011-07-31End: 2012-02-29Updated: 2012-05-08
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
CompletedNCT01594983
Start: 2012-06-30End: 2013-07-31Updated: 2020-12-17
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
CompletedNCT01811472
Start: 2013-06-30End: 2014-09-30Updated: 2016-02-04
Phase 3
A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
CompletedNCT01514461
Start: 2012-07-31End: 2014-05-31Updated: 2015-06-03
Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.
TerminatedNCT01589237
Start: 2013-02-28End: 2015-07-31Updated: 2016-11-15